Company Announcement No 3. 2020-21: First half year 2020/21 Financial statement
Please find the financial statement for first half year 2020/21 in the attachment:AttachmentCompany_announcement_FY 2020-21_3_H1
Day: November 20, 2020
CSOL Holding Ltd. reports third quarter 2020 financial results
Written by Customer Service on . Posted in Earnings Releases And Operating Results.
CSOL Holding’s EBITDA for the first nine months of 2020 amounted to USD 55.5 million and the corresponding EBITDA margin was 27.3%. Sales amounted to USD 203.5 million, up 1.8% compared to the first nine months of 2019, mainly due to increases in mangoes, grapes, tangerines and avocados volumes. LTM Sales and EBITDA amounted to USD 330.2 million and USD 123.3 million respectively. As of September 30th, 2020, the Company maintained a cash balance of USD 33.9 million and a net leverage ratio of 3.4x.The Company continues executing its strategy to become a year-round supplier of fresh fruit to our global clients complementing its Peruvian window operations with investments in Colombia, Uruguay and lately in Chile, and capitalizing on its commercial and logistic platforms.“Despite the global pandemic context, the Company has achieved...
Cellect Biotechnology Reports Third Quarter Financial and Operating Results; Recent Developments Position Company to Accelerate Progress in 2021
Written by Customer Service on . Posted in Earnings Releases And Operating Results.
Promising Progress on Clinical Development Progress, Collaborations and PartneringMutually Ended Discussion on Medical Cannabis Commercial and Merger AgreementsTEL AVIV, Israel, Nov. 20, 2020 (GLOBE NEWSWIRE) — Cellect Biotechnology Ltd. (NASDAQ: APOP), a developer of innovative technology which enables the functional selection of stem cells, today reported financial and operating results for the third quarter ended September 30, 2020. Subsequent to the end of the third quarter, the Company announced several other key achievements subsequent to the end of the third quarter that position it for continued success in 2021, including clinical and operational objectives:Initiated its clinical trial in the U.S. The trial is being performed at Washington University School of Medicine in St. Louis, Missouri, which is among the leading medical...
AGF annonce les distributions annuelles estimées réinvesties de gains en capital pour les FNB AGF
Written by Customer Service on . Posted in Dividend Reports And Estimates.
TORONTO, 20 nov. 2020 (GLOBE NEWSWIRE) — Placements AGF Inc. (AGF) a annoncé aujourd’hui les distributions annuelles estimées réinvesties de 2020, pour les FNB AGF inscrits à la Bourse de Toronto ou à la NEO Bourse. Ces distributions annuelles estimées réinvesties représentent généralement les gains en capital réalisés dans le cadre des FNB AGF. Elles ne seront pas versées en espèces, mais plutôt réinvesties et déclarées à titre de gains imposables.Les distributions annuelles réinvesties seront versées en tant que distributions théoriques. De telles distributions sont produites quand les parts associées aux distributions réinvesties sont immédiatement consolidées avec les parts qui étaient détenues avant la distribution. Le nombre de parts détenues après la distribution est ainsi identique au nombre de parts détenues auparavant....
AGF Announces Estimated Annual Reinvested Capital Gains Distributions for AGF ETFs
Written by Customer Service on . Posted in Dividend Reports And Estimates.
TORONTO, Nov. 20, 2020 (GLOBE NEWSWIRE) — AGF Investments Inc. (AGF) today announced the estimated annual 2020 reinvested distributions for the AGF ETFs listed on the Toronto Stock Exchange or NEO Exchange. These estimated annual reinvested distributions generally represent realized capital gains within the AGF ETFs and will not be paid in cash, but will be reinvested and reported as taxable.The annual reinvested distributions will be paid in the form of a notional distribution. A notional distribution is when the units from a reinvested distribution are immediately consolidated with the units held prior to the distribution. The number of units held after the distribution is therefore identical to the number of units held before the distribution. The unitholder’s adjusted cost base for the respective AGF ETF may increase.Further...
Jushi Holdings Inc. Increases Equity Ownership Interest in Dalitso LLC, the Company’s Majority-Owned, Virginia-Based Pharmaceutical Processor Permit Holder
Written by Customer Service on . Posted in Public Companies.
Jushi Holdings Inc. Increased Equity Ownership Interest in Dalitso LLC to 79%BOCA RATON, Fla., Nov. 20, 2020 (GLOBE NEWSWIRE) — Jushi Holdings Inc. (“Jushi” or the “Company”) (CSE: JUSH) (OTCMKTS: JUSHF), a vertically integrated, multi-state cannabis operator, announced it has purchased an additional 17.235% of the issued and outstanding equity of Dalitso LLC (Dalitso), a Virginia-based pharmaceutical processor. The Company now owns 79% of the issued and outstanding equity of Dalitso.Dalitso is one of only five applicants to have received conditional approval for a pharmaceutical processor permit issued by the Virginia Board of Pharmacy, and one of only four to have received final approval and permit issuance in the Commonwealth. Dalitso’s permit allows the Dalitso to cultivate, process, dispense and deliver medical cannabis to...
Man Group PLC : Form 8.3 – CPL Resources plc
Written by Customer Service on . Posted in Mergers And Acquisitions.
Ap19FORM 8.3IRISH TAKEOVER PANELDISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE1. KEY INFORMATIONINTERESTS AND SHORT POSITIONS Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)(b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3)Ap20DEALINGS (Note 4) Purchases and sales(b) Derivatives transactions (other than options transactions)(c) Options transactions in respect of existing relevant securities(i) Writing, selling, purchasing or varying(ii) Exercising(d) Other dealings (including transactions in respect of new securities) (Note 4)Ap212. OTHER INFORMATIONAgreements,...
Ebix Declares 7.5 Cent Quarterly Dividend, Payable December 15, 2020, to Shareholders of Record December 1, 2020
Written by Customer Service on . Posted in Dividend Reports And Estimates.
JOHNS CREEK, Ga., Nov. 20, 2020 (GLOBE NEWSWIRE) — Ebix, Inc., (NASDAQ: EBIX) a leading international supplier of On-Demand software and E-commerce services to the insurance, financial, healthcare and e-learning industries, today announced that its Board of Directors has declared a regular quarterly dividend of 7.5 cents per common share. The dividend is payable December 15, 2020 to shareholders of record at the close of business on December 1, 2020.About Ebix, Inc.With 50+ offices across 6 continents, Ebix, Inc., (NASDAQ: EBIX) endeavors to provide On-Demand software and E-commerce services to the insurance, financial, healthcare and e-learning industries. In the Insurance sector, Ebix’s main focus is to develop and deploy a wide variety of insurance and reinsurance exchanges on an on-demand basis, while also, providing Software-as-a-Service...
Todos Medical Announces Positive In Vitro Data for Tollovid™ Confirming 3CL Protease Inhibition Mechanism of Action
Written by Customer Service on . Posted in Public Companies.
NEW YORK, NY, REHOVAT, ISRAEL, SINGAPORE, Nov. 20, 2020 (GLOBE NEWSWIRE) — via NewMediaWire — Todos Medical (OTCQB: TOMDF), an in vitro diagnostics company focused on distributing comprehensive solutions for COVID-19 screening and diagnosis, and developing blood tests for early detection of cancer and Alzheimer’s disease, today announced positive in vitro data by its joint venture partner NLC Pharma for the Company’s dietary supplement Tollovid™, demonstrating its ability to inhibit the 3CL protease. The 3CL protease is an enzyme that is required for the intracellular replication of coronaviruses. Tollovid received a certificate of free sale from the FDA in August 2020 and is being launched commercially into the US market initially at botanical wellness store The Alchemist’s Kitchen™ in New York City.As part of NLC Pharma’s...
Destination XL Group, Inc. Reports Third Quarter Financial Results
Written by Customer Service on . Posted in Earnings Releases And Operating Results.
CANTON, Mass., Nov. 20, 2020 (GLOBE NEWSWIRE) — Destination XL Group, Inc. (NASDAQ: DXLG), the largest omni-channel specialty retailer of big and tall men’s clothing, today reported operating results for the third quarter of fiscal 2020 and provided a business update with respect to the COVID-19 pandemic.Third Quarter Financial HighlightsTotal sales for the third quarter were $85.2 million, down 20.1% from $106.6 million in the prior-year third quarter.Cash Flow from operations for the first nine months of ($8.6) million as compared to the prior year of $(14.4) million. Free Cash Flow was ($11.6) million as compared to ($25.4) million last year.Net loss for the third quarter was $(7.0) million as compared to a net loss of $(7.2) million in the prior year’s third quarter.Adjusted EBITDA for the third quarter was $(1.7) million...
